Nicholls 2025 — SURPASS-CVOT Tirzepatide

New England Journal of Medicine

Nicholls SJ, et al.

Summary

Tirzepatide CVOT

Study Details

Study Design

Phase 3 double-blind CVOT

Indication

CV outcomes in T2D and obesity

Intervention

Tirzepatide

Species

Human

Sample Size

13,600 subjects